Population pharmacokinetics of doxorubicin in Indian cancer patients using NONMEM

References

• Martínez R, Chacón-García L. The search of DNA-intercalators as antitumoral drugs: what worked and what did not work. Curr Med Chem 2005;12:127–151.
   PubMed Web of Science ®Google Scholar
• Buick RN, Messner HA, Till JE, McCulloch EA. Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man. J Natl Cancer Inst. 1979; 62(2):249–55.
   PubMed Web of Science ®Google Scholar
• Giovanni Capranico, Paola De Isabella, Sergio Penco, Stella Tinelli and Franco Zunino. Role of DNA breakage in cytotoxicity of Doxorubicin, 9-Deoxydoxorubicin, and 4-­Demethyl-6-deoxydoxorubicin in Murine Leukemia P388 cells. Cancer Research 1989; 49:2022–2027.
   PubMed Web of Science ®Google Scholar
• Zoli W, Ulivi P, Tesei A, Fabbri F, Rosetti M, Maltoni R, Giunchi DC, Ricotti L, Brigliadori G, Vannini I and Amadori D. Addition of 5-­fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res 2005;7:R681–R689.
   PubMed Web of Science ®Google Scholar
• Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996;7:687–693.
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Wickerham DL, Bowman D, Legault-Poisson S, Schipper H, Wolmark N, Sass R, Fisher ER and Jochimsen P. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience J Clin Oncol 1989;7:572–582.
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E and Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency Eur J Cancer 2007;43:14–34.
   PubMed Web of Science ®Google Scholar
• Rudeka MA, Sparreboomb ES, GarrettMayerc D. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 2004;40:1170–1178.
   PubMed Web of Science ®Google Scholar
• Mathijssen RHJ, De Jong FA, Loos WJ, van der Bol Jyn, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area-based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007;12:913–9230
   PubMed Web of Science ®Google Scholar
• Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001;19:171–177.
   PubMed Web of Science ®Google Scholar
• Sandanaraj E, Lal S, Selvarajan V. London Lucien Ooi PXR pharmacogenetics: Association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 2008;14:7116–7126.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Robert J, Van Der Vijgh WJF. Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol 1991;9:871–876.
   PubMed Web of Science ®Google Scholar
• Sripuram VK, Kaushik HK, Bedada SK, Reddy NY, Devarakonda KR. Development and validation of rapid and sensitive HPLC method for the determination of doxorubicin in human plasma. AAPS Annual Meeting and Exposition 2008. November 17–19, 2008. Georgia World Congress Center Atlanta, GA, USA.
   Google Scholar
• Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991;32:669–670.
   PubMed Web of Science ®Google Scholar
• Girard P, Sheiner LB, Kastrissios H, Blaschke TF. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm 1996;24:265–282.
   PubMedGoogle Scholar
• Freyer G, Tranchand B, Ligneau B, Adriet C, Souquet PJ, Fortune C, Riou R, Rebuttu P, Boissel JP, Trillet-Lenoir V and Girard P. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicenter study. Br J Clin Pharmacol 2000;50:315–324.
   PubMed Web of Science ®Google Scholar
• Sandanaraj E, Savic R, Lal S, Wong ZW, Ang Peter CS, Wong NS, Holford N, Karlson MO and Chowbay B. Population pharmacokinetics of doxorubicin and doxorubicinol in Asian breast cancer patients J Clin Oncol 2008;26(suppl):abstr 13501.
   Google Scholar